EMA’s safety committee elects new chair
Submitted by Anonymous (not verified) on 11 July 2024 - 11:58
EMA’s safety committee elects new chair
Timetable: Initial (full) marketing authorisation application accelerated assessment timetables
Submitted by Anonymous (not verified) on 11 July 2024 - 11:11
Timetable: Initial (full) marketing authorisation application accelerated assessment timetables
Human medicines European public assessment report (EPAR): Rybrevant, amivantamab, Date of authorisation: 09/12/2021, Revision: 4, Status: Authorised
Submitted by Anonymous (not verified) on 11 July 2024 - 11:02
Human medicines European public assessment report (EPAR): Rybrevant, amivantamab, Date of authorisation: 09/12/2021, Revision: 4, Status: Authorised
Human medicines European public assessment report (EPAR): Truqap, capivasertib, Date of authorisation: 17/06/2024, Status: Authorised
Submitted by Anonymous (not verified) on 11 July 2024 - 11:00
Human medicines European public assessment report (EPAR): Truqap, capivasertib, Date of authorisation: 17/06/2024, Status: Authorised
Timetable: Initial (Full) marketing authorisation application - ATMP
Submitted by Anonymous (not verified) on 11 July 2024 - 10:47
Timetable: Initial (Full) marketing authorisation application - ATMP
Annual activity report 2023
Submitted by Anonymous (not verified) on 11 July 2024 - 10:35
Annual activity report 2023
Annual reports and work programmes
Submitted by Anonymous (not verified) on 11 July 2024 - 10:35
Annual reports and work programmes
Academia
Submitted by Anonymous (not verified) on 11 July 2024 - 10:16
Academia
Cancer Medicines Forum: May 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 23 May 2024, 13:00 (CEST) to 23 May 2024, 16:00 (CEST)
Submitted by Anonymous (not verified) on 11 July 2024 - 10:15
Cancer Medicines Forum: May 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 23 May 2024, 13:00 (CEST) to 23 May 2024, 16:00 (CEST)
Human medicines European public assessment report (EPAR): Dimethyl fumarate Neuraxpharm, dimethyl fumarate, Date of authorisation: 22/04/2024, Status: Authorised
Submitted by Anonymous (not verified) on 11 July 2024 - 10:00
Human medicines European public assessment report (EPAR): Dimethyl fumarate Neuraxpharm, dimethyl fumarate, Date of authorisation: 22/04/2024, Status: Authorised